JP4409295B2 - Ｐｔｘ３遺伝子発現抑制方法 - Google Patents

Ｐｔｘ３遺伝子発現抑制方法 Download PDF

Info

Publication number
JP4409295B2
JP4409295B2 JP2003583400A JP2003583400A JP4409295B2 JP 4409295 B2 JP4409295 B2 JP 4409295B2 JP 2003583400 A JP2003583400 A JP 2003583400A JP 2003583400 A JP2003583400 A JP 2003583400A JP 4409295 B2 JP4409295 B2 JP 4409295B2
Authority
JP
Japan
Prior art keywords
group
groups
expression
gene expression
ptx3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003583400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005522490A5 (enExample
JP2005522490A (ja
Inventor
滋 森川
明糸 泉
隆雄 浜窪
龍彦 児玉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Nissan Chemical Corp
Original Assignee
Kowa Co Ltd
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd, Nissan Chemical Corp filed Critical Kowa Co Ltd
Publication of JP2005522490A publication Critical patent/JP2005522490A/ja
Publication of JP2005522490A5 publication Critical patent/JP2005522490A5/ja
Application granted granted Critical
Publication of JP4409295B2 publication Critical patent/JP4409295B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003583400A 2002-04-15 2003-04-11 Ｐｔｘ３遺伝子発現抑制方法 Expired - Fee Related JP4409295B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37211402P 2002-04-15 2002-04-15
US10/196,428 US20030195167A1 (en) 2002-04-15 2002-07-17 PTX3-gene expression inhibitor
PCT/JP2003/004603 WO2003086380A1 (en) 2002-04-15 2003-04-11 Ptx3 gene expression suppressing method

Publications (3)

Publication Number Publication Date
JP2005522490A JP2005522490A (ja) 2005-07-28
JP2005522490A5 JP2005522490A5 (enExample) 2006-02-09
JP4409295B2 true JP4409295B2 (ja) 2010-02-03

Family

ID=28794074

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003583400A Expired - Fee Related JP4409295B2 (ja) 2002-04-15 2003-04-11 Ｐｔｘ３遺伝子発現抑制方法

Country Status (9)

Country Link
US (2) US20030195167A1 (enExample)
EP (1) EP1494661B1 (enExample)
JP (1) JP4409295B2 (enExample)
AT (1) ATE445395T1 (enExample)
AU (1) AU2003226456A1 (enExample)
DE (1) DE60329668D1 (enExample)
MY (1) MY137134A (enExample)
TW (1) TWI349547B (enExample)
WO (1) WO2003086380A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1614429A4 (en) * 2003-04-17 2007-05-02 Kowa Co LKLF / KLF2 GEN-EXPRESSIONSPROMOTER
JP2007512347A (ja) * 2003-11-26 2007-05-17 デューク・ユニバーシティー 緑内障を予防するかまたは治療する方法
ITRM20030596A1 (it) * 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
WO2005080981A1 (ja) * 2004-02-25 2005-09-01 Perseus Proteomics Inc. 血管障害の程度の判定方法
WO2005105069A1 (en) * 2004-04-26 2005-11-10 Alcon, Inc. Statins for the treatment of ocular hypertension and glaucoma
WO2008001499A1 (en) * 2006-06-29 2008-01-03 Kowa Co., Ltd. Prophylactic and/or therapeutic agent for rheumatoid arthritis
CN106950366B (zh) * 2017-02-15 2019-03-22 中国医学科学院北京协和医院 一种acpa阴性的ra诊断标志物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244916A (en) * 1992-01-31 1993-09-14 The Scripps Research Institute Inhibition of respiratory burst using posttranslational modification inhibitors
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
JP2002539108A (ja) * 1999-03-08 2002-11-19 メルク エンド カムパニー インコーポレーテッド 結晶質水和ジヒドロキシオープンアシッドシンバスタチンカルシウム塩
US6403637B1 (en) * 1999-08-09 2002-06-11 Univ Saint Louis Methods of modulating matrix metalloproteinase activity and uses thereof
US20030018040A1 (en) * 2000-02-10 2003-01-23 Yasuo Sugiyama Tnf-alpha inhibitors
JP2004512278A (ja) * 2000-09-19 2004-04-22 ノビムーヌ　ソシエテ　アノニム 新規な免疫調節剤、免疫阻害剤、及び抗炎症剤としてのスタチン（ＨＭＧ−ＣｏＡリダクターゼ阻害剤）
US20020159974A1 (en) * 2000-09-19 2002-10-31 Francois Mach Treatment of multiple sclerosis with statins (HMG-CoA reductase inhibitors)

Also Published As

Publication number Publication date
ATE445395T1 (de) 2009-10-15
AU2003226456A1 (en) 2003-10-27
MY137134A (en) 2008-12-31
TWI349547B (en) 2011-10-01
US20030195167A1 (en) 2003-10-16
JP2005522490A (ja) 2005-07-28
EP1494661A1 (en) 2005-01-12
TW200403990A (en) 2004-03-16
US20080161348A1 (en) 2008-07-03
DE60329668D1 (de) 2009-11-26
AU2003226456A8 (en) 2003-10-27
EP1494661B1 (en) 2009-10-14
WO2003086380A1 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
US20080161348A1 (en) Ptx3-gene expression inhibitor
JP2008526861A (ja) 炎症性障害を治療するための薬剤併用療法および医薬組成物
US20100063070A1 (en) Combination for use in the treatment of inflammatory disorders
WO2005115397A2 (en) Compositions and treatments for modulating kinase and/or hmg-coa reductase
CN1230173C (zh) 糖尿病合并症预防及治疗剂
US20130210860A1 (en) Prophylactic and/or therapeutic agent against lymphedema
JP4719572B2 (ja) Ｌｋｌｆ／ｋｌｆ２遺伝子発現促進剤
EP1894576B1 (en) Novel triglyceride reducing agent
US9345671B2 (en) Adiponectin production enhancer
JP2010523486A (ja) 炎症疾患の治療において使用するための新規な組み合わせ
JP4187141B2 (ja) 新規なトロンボモジュリン発現促進剤
EP2033646A1 (en) Prophylactic and/or therapeutic agent for rheumatoid arthritis
JP2005232150A (ja) アディポネクチン産生増強剤
HK1060311B (en) Preventives and remedies for complications of diabetic
JPWO2005079846A1 (ja) Ｒａｃタンパク質の核内移行促進剤及びそのスクリーニング方法
HK1111632B (en) Novel triglyceride reducing agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091001

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091110

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091111

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121120

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121120

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131120

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees